Invion Stock

Invion Liabilities

The Liabilities of Invion (IVX.AX) as of Sep 3, 2026.

Liabilities

0.00AUD

Last updated:

In 2026, Invion's total liabilities amounted to 0.00 AUD, a % difference from the 0.00 AUD total liabilities in the previous year.

The Invion Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2016
5.99 M AUD
Jan 1, 2017
1.80 M AUD
Jan 1, 2018
2.44 M AUD
Jan 1, 2019
604,700.00 AUD
Jan 1, 2020
326,800.00 AUD
Jan 1, 2021
851,500.00 AUD
Jan 1, 2022
462,400.00 AUD
Jan 1, 2023
651,000.00 AUD
The Invion Liabilities history
YEARLiabilitiesYoY
651,000.00AUD+40.79%
462,400.00AUD-45.70%
851,500.00AUD+160.56%
326,800.00AUD-45.96%
604,700.00AUD-75.24%
2.44 MAUD+35.34%
1.80 MAUD-69.88%
5.99 MAUD+199.41%
2.00 MAUD+199.28%
668,800.00AUD-87.19%
5.22 MAUD+536.59%
820,000.00AUD-88.05%
6.86 MAUD-25.92%
9.26 MAUD-19.69%
11.53 MAUD+78.21%
6.47 MAUD+114.24%
3.02 MAUD-66.89%
9.12 MAUD
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Invion's Liabilities

Invion's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Invion's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Invion's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Invion's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Invion’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Invion stock

On Eulerpool you can find the complete historical development of The Liabilities Invion since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Invion historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Invion

All Key Metrics — Invion